Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026



Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > News?
View:
Post by Nunavuttrader on Feb 09, 2022 11:40am

News?

When do we expect big news? What are the predictions of where this stock could go and in what timeframe?
Comment by Yajne on Feb 09, 2022 11:45am
Update on Ph2 trial expected "SOON" which will confirm the data needed to apply for break through designation (BTD) for TLD-1433. IMO this will propel sp above $1 initially and possibly significantly higher depending on the full content of the long-awaited NR. JMHO
Comment by Retireyoung on Feb 09, 2022 11:57am
I understand people selling this stock to take a bit of profit but I believe some might regret it. Patience should pay off big time with this stock.
Comment by robertshaw on Feb 09, 2022 11:59am
if we could get the former 7 patients (270 days cancer free) all printed out  to be  360 days cancer free( and the former 7 patients which are 180 days cancer free to 270 days cancer free), by the end of this month, we can see $30+ before BTD comes....
Comment by robertshaw on Feb 09, 2022 12:11pm
Blowjobjoe once bet against  me in Phase1 for the 5th patient 's 270 days cancer free result after we got the 5th patient 180 days cancer free, I said 270 days cancer free after 180 days cancer free is a given, he insisited no so sure.... but I won...and it did turned out to be 270 days cancer free when the time hit...,  I miss Blowjobjoe, because no one dare to bet like him against ...more  
Comment by menoalittle on Feb 09, 2022 12:21pm
>> bet against science ,  need a lots courage. unless it's from CNN (or such.) but against the real deal? seems like more a sheer lack of intelligence...
Comment by Oilminerdeluxe on Feb 09, 2022 12:13pm
$30 is fine by me. Won't complain one bit.  Not sure much will be mentioned just yet on the other indications, but man do I want it. But the data coming is of course the most important thing right now. Quite interesting. We could see one of those 30 million shares traded days when it arrives.  
Comment by robertshaw on Feb 09, 2022 12:20pm
Blowjobjoe's bosses together with southertiertom's gang naked shorted over 20M shares on Aug 22nd ,2019 in a single day  around 0.26 ... and they still  didn't cover yet... we could make them to pay  over $30+/share... 
Comment by menoalittle on Feb 09, 2022 12:17pm
>> by the end of this month, we can see $30+ before BTD comes.... will likely require rose colored glasses, but dang... me loves the optimism!
Comment by robertshaw on Feb 09, 2022 12:23pm
if we short squeeze blowjobjoe's bosses with that data... $30+ is possible...
Comment by menoalittle on Feb 09, 2022 12:39pm
personally, I think this incredibly secret and monstrously large short position that you incessantly refer to is a figment of your imagination... do you take drugs?
Comment by Nunavuttrader on Feb 09, 2022 12:51pm
Quick get on wallstreetbets
Theralase Technologies Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     


Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250